# Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma

> **NCT02360501** · PHASE2 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 50 (actual)

## Conditions studied

- Nasopharyngeal Neoplasms

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Cisplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02360501
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2016-03
- **Final completion:** 2016-04
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2016-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02360501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02360501, "Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02360501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*